Conduct Disorder
Conditions
Keywords
mentalization-based treatment, conduct disorder, adolescents
Brief summary
A feasibility and pilot trial to investigate the feasibility of a newly manualized psychotherapy Mentalization-Based Training for Adolescents with Conduct Disorder (MBT-CD)
Detailed description
Background: Conduct Disorder is a severe and complex mental disorder with the highest incidence in adolescence. Previous studies have shown that family-oriented interventions are effective in the treatment of Conduct Disorder. However, most therapies focus rather on symptom management and less on etiological causes without inclusion of the family in the therapeutic process. Previous research has linked specific symptoms of Conduct Disorder with deficits in mentalization ability. Mentalization is the ability to perceive one's own and other's behavior as the product of affective and cognitive mental states. Low or missing mentalization abilities are regarded as a risk factor for the development and chronification of Conduct Disorder. Aims: The study aims to investigate the feasibility of a newly manualized psychotherapy Mentalization-Based Training for Adolescents with Conduct Disorder (MBT-CD) that strives to decrease symptoms associated with Conduct Disorder by increasing mentalization in adolescents and their families. Methods: The study is feasibility and piolot trial, carried out in Heidelberg (Germany), and Mainz (Germany). Adolescents aged between 11-18, who meet the DSM-5 criteria for Conduct Disorder will receive MBT-CD. Times of measurement: t0 (Screening), T1 (Baseline, at the beginning of therapy), T2 (3 months after the beginning of therapy), T3 (at the end of therapy, after 6 months), T4 (follow-up, after 9 months).
Interventions
OTHERMBT-CD
MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
Sponsors
Heidelberg University, Psychotherapy Research Department
Heidelberg University, Clinic for Child and Youth Psychiatry
Johannes Gutenberg University Mainz
Heidelberg University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
11 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* main diagnosis conduct disorder (DSM-5 312.81,312.82) * written informed consent
Exclusion criteria
* acute substance dependence * sexual offenses * acute psychotic symptoms, early or early-onset schizophrenia * neurological impairments and low intelligence (IQ \<80) * non-German-speaking * other clinical contra indication for outpatient psychotherapy (e.g. acute suicidality)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) | Change from baseline in SCID-II at 12 months (at the end of therapy) |
| Reactive-Proactive-Aggression Questionnaire (RPQ) | Change from baseline in RPQ at 6 months |
| Subtypes of Antisocial Behaviour Questionnaire (STAB) | Change from baseline in STAB at 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reflective Functioning Questionnaire (RFQ) | Change from baseline in RFQ at 12 months (at the end of therapy) | — |
| Levels of Personality Functioning - Questionnaire Adolescence (LoPF-QA) | Change from baseline in LoPF-QA at 12 months (at the end of therapy) | — |
| Movie for the Assessment of Social Cognition (MASC) | Change from baseline in MASC at 12 months (at the end of therapy) | — |
| 10 round Trust Game Task (TGT) | Change from baseline in TGT at 12 months (at the end of therapy) | — |
| Social Hierarchy Task (SHT) | Change from baseline in SHT at 12 months (at the end of therapy) | — |
| Approach-Avoidance Task (AAT) | Change from baseline in AAT at 12 months (at the end of therapy) | — |
| Symptom Checklist-90-Revised (SCL-90R) | Change from baseline in SCL-90R at 12 months (at the end of therapy) | — |
| Stress Index for Parents of Adolescents (SIPA) | Change from baseline in SIPA at 12 months (at the end of therapy) | — |
| drop-out rates | after 12 months (at the end of therapy) | — |
| cost-effectiveness | after 12 months (at the end of therapy) | Cost-effectiveness will be measured by participation in training/school, rehospitalization, internment |
| Global Assessment of Functioning (GAF) | Change from baseline in GAF at 12 months (at the end of therapy) | — |
| Clinical Global Impression (CGI-SI) | Change from baseline in CGI-SI at 12 months (at the end of therapy) | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| The Mini-International Neuropsychiatric Interview (MINI) | Change from baseline in MINI at 12 months (at the end of therapy) | Treatment related variable (moderator) |
| Youth Psychopathy Traits Inventory (YPI) | only baseline assessment | Treatment related variable (moderator) |
| Cultural-Fair-Test (CFT-2) | only baseline assessment | Treatment related variable (moderator) |
| Childhood Experience of Care and Abuse Questionnaire (CECA-Q) | only baseline assessment | Treatment related variable (moderator) |
| Dimensional Assessment of Personality Pathology - Basic Questionnaire (DAPP-BQ) | only baseline assessment | Treatment related variable (moderator) |
| Emotion Regulation Questionnaire (ERQ) | Change from baseline in ERQ at 12 months (at the end of therapy) | Treatment related variable (moderator) |
| Experiences in Close Relationships - Revised (ECR-R) | Change from baseline in ECR-R at 12 months (at the end of therapy) | Treatment related variable (moderator) |
| Zurich Brief Questionnaire for the Assessment of Parental Behaviors (ZKE) | Change from baseline in ZKE at 12 months (at the end of therapy) | Treatment related variable (moderator) |
| Working Alliance Inventory (WAI) | Change from baseline in WAI at 6 months | Treatment related variable (moderator) |
Countries
Germany
Outcome results
None listed